Odyssey Therapeutics, Inc. (ODTX)

Odyssey Therapeutics, Inc. (ODTX) is a clinical-stage biotechnology company based in the Boston area that discovers and develops precision medicines for autoimmune, inflammatory and oncology diseases. Founded in 2021, the company was built to pursue difficult drug targets using a combination of structure-based chemistry, protein engineering and computational and machine learning tools.

Its pipeline includes small-molecule and biologic candidates aimed at key signaling pathways in the immune system, with programs such as a RIPK2 inhibitor for inflammatory conditions like inflammatory bowel disease, along with other immunology and cancer programs at earlier stages. The company seeks to design molecules with improved selectivity and potency against targets that have been difficult to address with conventional approaches.